Advertisement
Advertisement

Archive

Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: http://dx.doi.org/10.1160/TH08-03-0193
Issue: 2008: 100/1 (July) pp. 1-171
Pages: 26-31

Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry

Nuria Ruíz-Giménez 1, Carmen Suárez 1, Rocío González 2, José Antonio Nieto 3, José Antonio Todolí 4, Ángel Luis Samperiz 5, Manuel Monreal 6, and the RIETE Investigators*
1 Servicio de Medicina Interna, Hospital de la Princesa, Madrid, Spain; 2 Fundación de Investigación Biomédica, Hospital de la Princesa, Madrid, Spain; 3 Servicio de Medicina Interna, Hospital Virgen de la Luz, Cuenca, Spain; 4 Servicio de Medicina Interna, Hospital Universitario La Fe, Valencia, Spain; 5 Servicio de Medicina Interna, Hospital Reina Sofia de Tudela, Navarra, Spain; 6 Servicio de Medicina Interna, Hospital Germans Trias i Pujol, Badalona, Spain

Keywords

Prediction, bleeding complications, venous thromboembolism

Summary

A score that can accurately determine the risk of major bleeding during anticoagulant therapy may help to make decisions on anticoagulant use. RIETE is an ongoing registry of consecutive patients with acute venous thromboembolism (VTE). We composed a score to predict the risk for major bleeding within three months of anticoagulant therapy. Of 19,274 patients enrolled, 13,057 (67%) were randomly assigned to the derivation sample, 6,572 to the validation sample. In the derivation sample 314 (2.4%) patients bled (fatal bleeding, 105). On multivariate analysis, age >75 years, recent bleeding, cancer, creatinine levels >1.2 mg/dl, anemia, or pulmonary embolism at baseline were independently associated with an increased risk for major bleeding. A score was composed assigning 2 points to recent bleeding, 1.5 to abnormal creatinine levels or anemia, 1 point to the remaining variables. In the derivation sample 2,654 (20%) patients scored 0 points (low risk); 9,645 (74%) 1–4 points (intermediate); 758 (5.8%) >4 points (high risk). The incidences of major bleeding were: 0.3% (95% confidence interval [CI]: 0.1–0.6), 2.6% (95% CI: 2.3–2.9), and 7.3% (95% CI: 5.6–9.3), respectively. The likelihood ratio test was: 0.14 (95% CI: 0.07–0.27) for patients at low risk;2.96 (95% CI:2.18–4.02) for those at high risk. In the validation sample the incidence of major bleeding was: 0.1%, 2.8%, and 6.2%, respectively. In conclusion, a risk score based on six variables documented at entry can identifyVTE patients at low, intermediate, or high risk for major bleeding during the first three months of therapy.

You may also be interested in...

1.
Urs Kistler 1, Inès Kramers-de Quervain 2, Urs Munzinger 3, Nils Kucher4

Thromb Haemost 2008 99 6: 1049-1052

http://dx.doi.org/10.1160/TH08-01-0019

2.
The Austrian Study on Recurrent Venous Thromboembolism (AUREC)

P. A. Kyrle (1), L. Eischer (1)

Hämostaseologie 2013 33 3: 201-209

http://dx.doi.org/10.5482/HAMO-13-03-0018

3.
Nienke Folkeringa 1, Michiel Coppens 2, Nic J. G. M. Veeger 1, Victor J. J. Bom 3, Saskia Middeldorp 2, Karly Hamulyak 4, Martin H. Prins 5, Harry R. Büller 2, Jan van der Meer1

Thromb Haemost 2008 100 1: 38-44

http://dx.doi.org/10.1160/TH07-11-0659